Agile Therapeutics

AGRX

Market cap $1.78M

PRINCETON, N.J., March 25, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX) (“Agile Therapeutics” or the “Company”), a women's healthcare company, today announced that the Company has received a final delisting notice from Nasdaq.

PRINCETON, N.J., March 21, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced it will report fourth quarter and full year 2023 financial results before the market opens on Thursday, March 28, 2024.

PRINCETON, N.J., March 20, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced it will report fourth quarter and full year 2023 financial results before the market opens on Friday, March 22, 2024.

Elimination of Remaining Debt to Perceptive Advisors Leaves the Company's Balance Sheet Debt Free Elimination of Remaining Debt to Perceptive Advisors Leaves the Company's Balance Sheet Debt Free

PRINCETON, N.J., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX) (“Agile Therapeutics” or the “Company”), a women's healthcare company, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 3,892,572 shares of common stock of the Company originally issued in July 2022 and May 2023, having an exercise price of $3.69 per share, at a reduced exercise price of $1.25 per share. The shares of common stock issuable upon exercise of the warrants are registered pursuant to effective registration statements on Form S-1 (File Nos. 333-271249 and 333-264960) and Form S-1MEF (File No. 333-265959). The gross proceeds to the Company from the exercise of the warrants are expected to be approximately $4.8 million, prior to deducting placement agent fees and estimated offering expenses.

Agile Therapeutics (NASDAQ: AGRX ) stock is rocketing higher on Thursday alongside heavy trading of the women's healthcare company's shares. During pre-market trading this morning, more than 7.5 million shares of AGRX stock have been traded.

Company Granted Extension by Nasdaq Hearings Panel to Regain Compliance with the Stockholders' Equity Continued Listing Requirement Until March 25, 2024

Implementation of the New Guidance Could Eliminate Financial Barriers for Contraceptive Products like Twirla® for 49 Million Women

The Company Commends House Committee on Oversight and Accountability Ranking Member Jamie Raskin for New Report on Contraception Coverage Gaps

Whether you subscribe to the idea that penny stocks are always a buy or determine your strategy based on broader market conditions, chances are that cheap stocks are on your watch list. While these sweeping market trends might not influence low-priced equities, it's important to understand what's going on in the stock market today.